TABLE 1.
Study cohort description.
| NHL | Lung cancer | Glioma | |
| Number of patients | 19 | 5 | 12 |
| Mean age of diagnosis (range) | 56 (21–76) | 61 (58–74) | 36 (18–62) |
| Sex | |||
| Male | 16 (84%) | 5 (100%) | 6 (50%) |
| Female | 3 (16%) | 0 | 6 (50%) |
| Immune status/localization | |||
| immunocompromised HIV + /systemic | 5 (26.3%) | NA | NA |
| immunocompromised PTLD/systemic | 8 (42.1%) | NA | NA |
| immunocompromised HIV + /CNS | 1 (5.2%) | NA | NA |
| immunocompromised PTLD/CNS | 5 (26.3%) | NA | NA |
| immunocompromised HIV + /Lung | NA | 5 (100%) | NA |
| Immunocompetent/CNS | 0 | NA | 12 (100%) |
| Histology | |||
| Monomorphic B-cell PTLD (9) | Non small cell adenocarcinoma (5) | Ganglioglioma (2) | |
| Polymorphic PTLD (3) | Glioblastoma (4) | ||
| DLBCL (3) | Oligodendroglioma (3) | ||
| Burkitt lymphoma (1) | Astrocytoma(3) | ||
| Marginal zone lymphoma (1) | |||
| Plasmablastic lymphoma(1) | |||
| HHV8 + DLBCL,NOS (1) | |||
| Stage | Ann Arbor for systemic NHL | TNM classification | |
| Stage I (4) | Stage I | Stage I (2) | |
| Stage II (0) | Stage II (2) | Stage II (2) | |
| Stage III (0) | Stage III (1) | Stage III (4) | |
| Stage IV (9) | Stage IV (2) | Stage IV (4) | |
| Spreading | Extranodal involvement | Metastasis | Metastasis |
| Yes (10) | Yes (2) | ||
| No (2) | No (3) | No (12) |
NHL, Non-Hodgkin lymphoma. CNS, central nervous system. DLBCL, diffuse large B cell lymphoma.